Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Galera Therapeutics, Inc. GRTX
$3.14
+$0.03 (0.80%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
141377906.00000000
-
week52high
3.50
-
week52low
1.12
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.82287000
-
EPS
-2.65000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 11:30
Описание компании
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B of A Securities | Underperform | Neutral | 27 мая 2022 г. |
| Citigroup | Buy | Buy | 20 дек 2021 г. |
| HC Wainwright & Co. | Buy | Neutral | 15 дек 2021 г. |
| BTIG | Buy | Neutral | 15 дек 2021 г. |
| HC Wainwright & Co. | Neutral | Buy | 20 окт 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Beardsley Robert A | D | 75651 | 10000 | 21 ноя 2022 г. |
| Beardsley Robert A | A | 108191 | 10000 | 21 ноя 2022 г. |
| Beardsley Robert A | D | 85651 | 10000 | 12 сент 2022 г. |
| Beardsley Robert A | A | 98191 | 10000 | 12 сент 2022 г. |
| Kennedy Eugene P. | A | 150000 | 150000 | 01 сент 2022 г. |
| Alleva Lawrence M | D | 2325 | 4000 | 18 июл 2022 г. |
| West Linda | A | 58496 | 58496 | 01 июл 2022 г. |
| Cunningham Emmett | A | 0 | 15000 | 15 июн 2022 г. |
| POWELL MICHAEL | A | 20000 | 20000 | 15 июн 2022 г. |
| West Linda | A | 15000 | 15000 | 15 июн 2022 г. |
Новостная лента
Galera to Present at Piper Sandler Annual Healthcare Conference
GlobeNewsWire
22 ноя 2022 г. в 07:00
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:10 a.m. E.T.
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
GlobeNewsWire
26 сент 2022 г. в 07:00
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) and final data from its Phase 2 AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place October 23-26, 2022 in San Antonio, Texas. Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 07:00
MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:30 p.m. E.T.